Has Jill Marjama-Lyons, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,014 in general payments to Jill Marjama-Lyons, MD across 39 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jill Marjama-Lyons, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jill Marjama-Lyons, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jill Marjama-Lyons, MD

Neurology · Albuquerque, NMNPI 1366534570

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 39 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Medtronic accounts for 69.3% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $793 and has fallen 70.0% since, to $238 in 2025.

$2,014in general payments, 2019–2025

Across 39 payments — averaging $51.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$1K
Boston Scientific$156
Amneal Pharmaceuticals LLC$149
Avanir Pharmaceuticals, Inc.$115
Acadia Pharmaceuticals Inc$104
Neurocrine Biosciences, Inc.$59
plus $36 from 1 others

What the payments were for

Food & beverage$2,014100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	29	$1,396
Boston Scientific	2	$156
Amneal Pharmaceuticals LLC	3	$149
Avanir Pharmaceuticals, Inc.	1	$115
Acadia Pharmaceuticals Inc	1	$104
Neurocrine Biosciences, Inc.	1	$59
Abbott	2	$36

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,014 in reported general payments places this provider in the 65th percentile of 91 neurology providers in New Mexico.

See all neurology providers in New Mexico →

Medicare billing

Part B allowed, 2024

$171,338

Medicare patients

181

Services billed

2,280

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
NeuproRotigotine	70	$127,880
Carbidopa-Levodopa ErCarbidopa/Levodopa	575	$32,653
Carbidopa-LevodopaCarbidopa/Levodopa	705	$27,493
Entacapone	124	$24,369
RytaryCarbidopa/Levodopa	22	$20,378
Ropinirole ErRopinirole Hcl	85	$17,170
Rasagiline Mesylate	77	$14,379
Carbidopa	12	$8,886
AmantadineAmantadine Hcl	120	$7,899
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone	12	$7,339
RivastigmineRivastigmine Tartrate	115	$6,761
Pramipexole DihydrochloridePramipexole Di-Hcl	155	$5,018
Selegiline Hcl	47	$4,607
Gabapentin	166	$2,930
Midodrine Hcl	37	$2,526

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Amneal Pharmaceuticals LLCRytary	$149	$20,37822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 91 neurology providers in New Mexico.

Other neurology in Albuquerque

Elaine EdmondsAlbuquerque$610K
Kader AbdelerahmanAlbuquerque$607K
Timothy OwnbeyAlbuquerque$90K
Gerson Suarez CedenoAlbuquerque$44K
Corey FordAlbuquerque$27K
Diksha MohantyAlbuquerque$20K
Douglas BarrettAlbuquerque$19K
Vanessa Licona SanjuanAlbuquerque$16K
Daniel ShibuyaAlbuquerque$13K
Alfred van BaakAlbuquerque$10K

See the full list for New Mexico →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →